The significance of p53 and bcl-2 overexpression and other prognostic factors in transitional cell carcinoma of the bladder

Touloupidis, Stavros; Fatles, G.; Kalaitzis, Christos; Giatromanolaki, Alexandra; Sivridis, E; Simopoulos, Konstantinos; Rombis, V.

doi:10.1007/s11255-005-4763-3

Cited by 6 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results showed that the combined treatment of ginsenoside Rg3 and cisplatin was associated with the reduced level of expression in Bcl-2. Duggan et al showed that the downregulation of Bcl-2 protein enhanced mitomycin C induced apoptotic cell death in bladder cancer (20), although the prognostic significance of those findings was not consistent in the literature (21)(22)(23)(24). Bolenz et al also demonstrated that the addition of Bcl-2 antisense oligodeoxynucleotides enhanced the cytotoxic potential of cisplatin as well as other chemotherapeutic agents such as mitomycin C in transitional carcinoma cell lines (25).…”

Section: Discussionmentioning

confidence: 99%

Synergistic antitumor effect of ginsenoside Rg3 and cisplatin in cisplatin-resistant bladder tumor cell line

LEE¹,

LEE²,

Ho³

et al. 2014

Oncology Reports

View full text Add to dashboard Cite

Abstract. Cisplatin-based chemotherapy is the first-line treatment for metastatic urothelial cell carcinoma. However, for cisplatin-resistant cases, no chemotherapeutic agent has been established as a standard of treatment. This study aimed to investigate the synergistic antitumor effect of ginsenoside Rg3 on cisplatin in cisplatin-resistant bladder cancer cells (T24R2). T24R2 cells were treated with cisplatin and/or ginsenoside Rg3. Cell viability was assessed by the Cell Counting Kit-8 and clonogenic assays. Synergism between ginsenoside Rg3 and cisplatin was determined when the combination index was <1.0. Flow cytometry was used to evaluate the cell cycle distribution. To estimate the changes of proteins associated with the cell cycle and apoptosis following the treatment of ginsenoside Rg3, western blotting and densitometric assays were performed for caspase-3, -8 and -9, cyclin B1, Bcl-2, Bad, p21 and cytochrome c. The Cell Counting Kit-8 and clonogenic assays showed the synergistic antitumor effect of ginsenoside Rg3 on cisplatin, while the combination index was <1.0, confirming the synergism. Cell cycle alterations at the G2/M phase caused by cisplatin were greater after the combination with ginsenoside Rg3. Western blotting and densitometric assay showed that the expression of Bcl-2 was decreased after the combined treatment of ginsenoside Rg3 and cisplatin, whereas the expression of cytochrome c and caspase-3 were increased, suggesting the activation of the intrinsic apoptotic pathway. In conclusion, ginsenoside Rg3 inhibited the proliferation of cisplatin-resistant bladder cancer cells in a synergistic manner with cisplatin. Activation of the intrinsic apoptotic pathway and the enhancement of cell cycle alterations are possible explanations for this result.

show abstract

Section: Discussionmentioning

confidence: 99%

Synergistic antitumor effect of ginsenoside Rg3 and cisplatin in cisplatin-resistant bladder tumor cell line

LEE¹,

LEE²,

Ho³

et al. 2014

Oncology Reports

View full text Add to dashboard Cite

show abstract

“…Outside of our panel of biomarkers, there are several other exploratory markers that might be worth further research; these include: p21 [2,12,14,19], Her‐2 [72–75], Bax/bcl‐2 [76–79] and CD40 [80,81]. Epigenetic processes, such as DNA methylation and histone acetylation, also represent important mechanisms in carcinogenesis [4,5].…”

Section: Other Markersmentioning

confidence: 99%

Biomarkers in bladder cancer

Bryan¹,

Zeegers

James

et al. 2010

BJU International

View full text Add to dashboard Cite

Detailed molecular insights into bladder cancer biology might allow more detailed prognostication and optimization of treatment with the objective of improving patient outcome and quality of life. However, in bladder cancer research the search for biomarkers has been called into question and has even obtained notoriety. It is unlikely that any single marker will be able to improve prognostication for patients with bladder cancer above and beyond grade and stage, but a combination of multiple independent markers might more precisely predict the outcome. From a previous review, we identified seven biomarkers to study within the setting of the Bladder Cancer Prognosis Programme (BCPP), a 5‐year multicentre programme of research based at the University of Birmingham and funded by Cancer Research UK, investigating their effectiveness in predicting recurrence and progression. As part of the ongoing quality‐assurance process for BCPP we present an updated review of our selected biomarkers, as well as highlighting other recent important developments in bladder cancer research.

show abstract

“…This difference might be explained by the hormonal differences between men and women and social habits (tobacco smoking is more common in men). 1,18 In addition to the fact that androgen receptors have a major role in development of cancer, 1,18 which is much more active in men than in women. 1 Statistically, there was no significant correlation between Bcl2 over-expression and sex of the patients.…”

Section: 8mentioning

confidence: 99%

Bcl-2 over-expression in urothelial tumors of the bladder. An immunohistochemical study

Hamdi¹

2018

Ann Coll Med Mosul

View full text Add to dashboard Cite

Objectives:The aim was, to evaluate the frequency of Bcl-2 over-expression in urothelial tumors of the bladder in Mosul city, to correlate the over-expression with age and sex of the patients, and grade and stage of the tumors, and to compare the results with those of others. Methods: A retrospective case-series study was performed on 50 urinary bladder urothelial tumors. The samples were collected from Al-Jamhuri Teaching Hospital in Mosul city, during a period of 8 months from November 2012 through June 2013. Results: The patients' age was in the range of 23-91 years with a mean of 62.64 year, male:female ratio (9:1). Approximately half of them were in the seventh decade (42%). Bcl-2 immunoreactivity was observed in 42% of the cases, it was positive in 4/11 of papillary urothelial neoplasm of low malignant potential cases, 9/23 of low grade cases, and in 8/15 of high grade cases, and was negative in the one case of papilloma. It was observed in 2/2 of Tis stage, 4/14 of cases with Ta stage, 9/21 of T1 stage, and 6/11 of T2 stage. It was negative in the 2 cases of T4. Statistically Bcl-2 over-expression was not significantly related to the age and sex of the patients, as well as the grade, and stage of the tumors. However, it was mainly found in the 6th decade of life (42.8%), in males (90.5%), in low grade (42.9%), and in stage T1 (42.9%). Conclusion: Bcl2 over-expression was found in 42% of bladder urothelial tumors. Bcl2 over-expression mainly was observed in the 6 th decade of life (42.8%), in males (90.5%), in low grade carcinoma (42.9%), and stage T1 (42.9%). Age and sex of the patients, and grade, and stage of the tumors had no significant correlation with Bcl2 over-expression.

show abstract

The significance of p53 and bcl-2 overexpression and other prognostic factors in transitional cell carcinoma of the bladder

Cited by 6 publications

References 19 publications

Synergistic antitumor effect of ginsenoside Rg3 and cisplatin in cisplatin-resistant bladder tumor cell line

Synergistic antitumor effect of ginsenoside Rg3 and cisplatin in cisplatin-resistant bladder tumor cell line

Biomarkers in bladder cancer

Bcl-2 over-expression in urothelial tumors of the bladder. An immunohistochemical study

Contact Info

Product

Resources

About